Satellos Bioscience Inc. GAAP EPS of -$0.53
Satellos Bioscience Inc. reported a GAAP EPS of -$0.53 for Q3. The company had $53.0 million in cash and short-term investments as of Sept. 30, 2026, up from $27.7 million on Dec. 31, 2025, according to a press release.
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 2:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$MSLE
Relevance
6/10
Decision brief
The 30-second read
Low
01
Why it matters
The disclosure is a primary earnings release for a micro‑cap biotech, offering limited trading relevance.
02
Market read
First‑report earnings for a small biotech; modest novelty and low actionable insight.
03
What to watch
Cash burn rate and runway could be more material than the EPS number.
Relevance 6/10Novelty 6/10Timing: same-day release
Background
Satellos Bioscience reported its Q3 GAAP EPS of -$0.53 and cash position.
Market effects
Sector
minimal impact on biotech sector
Regional
none
Global
none
Counterpoint
What could challenge this read
The EPS miss may be priced in already for such a small cap.
Key entities
- companySatellos Bioscience Inc.
Biotech firm reporting Q3 results.
